STICHTING WORLD DUCHENNE ORGANIZATION

Their core work

World Duchenne Organization is a Netherlands-based patient advocacy foundation focused on Duchenne Muscular Dystrophy (DMD), a severe genetic muscle-wasting disease. They represent the patient voice in clinical research, contributing patient perspectives, recruitment networks, and real-world evidence to EU-funded health projects. Their involvement spans clinical trials for new DMD treatments, understanding brain involvement in dystrophinopathies, remote trial design, and behavioral models for treatment adherence. They serve as the bridge between the DMD patient community and the research/pharmaceutical ecosystem driving new therapies.

What they specialise in

How they've shifted over time

Their early H2020 involvement (2016-2018) centered on traditional clinical trials for DMD drug development (VISION DMD) and rare disease data platforms (SHARE4RARE). From 2019 onward, they shifted toward more complex, multi-dimensional research: remote clinical trial infrastructure (Trials@Home), neurocognitive dimensions of DMD (BIND), and behavioral models for treatment adherence (BEAMER). This evolution reflects a maturing organization moving from supporting individual drug trials to shaping how clinical research itself is designed and delivered for rare disease patients.

Moving toward patient-centered research infrastructure — designing how trials are run, not just participating in them — which makes them increasingly valuable for any consortium targeting rare disease clinical methodology.

How they like to work

World Duchenne Organization exclusively participates as a partner, never as coordinator, which is typical for patient organizations that contribute domain expertise and patient access rather than managing large research programs. With 96 unique partners across 20 countries from just 5 projects, they operate in large, well-funded consortia. This broad network means they bring connections to major clinical research centers and pharma companies across Europe, making them a well-connected entry point into the DMD research community.

Extensive network of 96 unique partners across 20 countries, built through participation in large health research consortia. Their connections span clinical research centers, pharmaceutical companies, and other patient organizations across the EU.

What sets them apart

As a dedicated Duchenne Muscular Dystrophy patient organization, they offer something no university or pharma company can: direct access to the DMD patient community, authentic patient perspectives, and legitimacy in patient-facing aspects of clinical research. Their portfolio demonstrates they are not a passive advocacy group — they are active research partners contributing to trial design, data collection, and behavioral science. For any consortium working on neuromuscular diseases, rare disease trials, or patient-centered research methods, they provide the patient engagement component that EU calls increasingly require.

Highlights from their portfolio

• Trials@Home
  Their largest project (EUR 435,800) building a Center of Excellence for remote decentralized clinical trials — a model that gained major relevance post-COVID and reshapes how rare disease trials are conducted.
• BIND
  Explores the under-studied neurocognitive side of Duchenne — learning difficulties, autism, and brain involvement — combining deep phenotyping with animal models and gene therapy research.
• BEAMER
  Most recent project (2021-2026) developing behavioral frameworks for patient treatment adherence, signaling a strategic move toward health outcomes and cost-effectiveness research.